维力医疗(603309) - 2024 Q3 - 季度财报
Well LeadWell Lead(SH:603309)2024-10-18 08:51

Guangzhou Weili Medical 2024 Third Quarter Report Overview Key Financial Data The company achieved robust financial growth in the first three quarters of 2024, with operating revenue up 8.53% and net profit attributable to shareholders up 15.85%, demonstrating enhanced core business profitability and healthy cash flow Key Financial Indicators for the First Three Quarters of 2024 | Item | Year-to-Date (YTD) (RMB) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 1,060,429,057.46 | +8.53% | | Net Profit Attributable to Shareholders of the Parent Company | 166,726,371.77 | +15.85% | | Net Profit Attributable to Shareholders Excluding Non-Recurring Gains/Losses | 160,016,558.68 | +21.18% | | Net Cash Flow from Operating Activities | 119,902,354.35 | +8.73% | | Basic Earnings Per Share (RMB/share) | 0.57 | +16.33% | | Weighted Average Return on Net Assets (%) | 9.08% | Increased 0.86 percentage points | | Total Assets (Period-End) | 2,737,309,086.28 | +5.07% (vs. end of previous year) | | Total Equity Attributable to Shareholders of the Listed Company (Period-End) | 1,837,424,022.80 | +1.12% (vs. end of previous year) | - The company's non-recurring gains and losses totaled 6.71 million RMB in the first three quarters of 2024, primarily from government grants (3.69 million RMB) and fair value change gains/losses from financial assets held (5.71 million RMB)45 Shareholder Information As of the reporting period end, the company had 18,292 common shareholders, with the top three holding approximately 50.07% of shares, and all three major shareholders having portions of their equity pledged - As of the end of the reporting period, the company had a total of 18,292 common shareholders6 Top Three Shareholders' Shareholding and Pledging Status | Shareholder Name | Shareholding Percentage (%) | Share Status | Pledged Quantity (shares) | | :--- | :--- | :--- | :--- | | Highbright Investment (Hong Kong) Co., Ltd. | 31.39 | Pledged | 26,000,000 | | Guangzhou Songwei Enterprise Management Consulting Co., Ltd. | 13.33 | Pledged | 19,350,000 | | Guangzhou Weiyue Trading Consulting Co., Ltd. | 5.35 | Pledged | 10,180,000 | Quarterly Financial Statements This section presents the unaudited consolidated balance sheet, income statement, and cash flow statement, detailing the company's financial position, operating results, and cash flow for the reporting period Consolidated Balance Sheet Analysis As of September 30, 2024, total assets reached 2.737 billion RMB, up 5.07% from year-end 2023, with total liabilities at 885 million RMB and an asset-liability ratio of 32.34%, driven by growth in construction in progress and increased borrowings Key Balance Sheet Item Changes (vs. End of 2023) | Item | September 30, 2024 (RMB) | December 31, 2023 (RMB) | Change Rate | | :--- | :--- | :--- | :--- | | Total Assets | 2,737,309,086.28 | 2,605,281,433.80 | +5.07% | | Total Liabilities | 885,346,293.00 | 768,368,160.46 | +15.22% | | Total Equity Attributable to Shareholders of the Parent Company | 1,837,424,022.80 | 1,817,095,135.04 | +1.12% | - Significant asset-side changes include construction in progress increasing from 327 million RMB to 415 million RMB, indicating ongoing capacity or project construction; accounts receivable rose from 189 million RMB to 239 million RMB, and inventories from 143 million RMB to 198 million RMB, reflecting business scale expansion910 - Significant liability-side changes include short-term borrowings increasing sharply from 90 million RMB to 190 million RMB, and long-term borrowings from 259 million RMB to 324 million RMB, indicating increased debt financing to support operations and investments1011 Consolidated Income Statement Analysis In the first three quarters of 2024, total operating revenue reached 1.06 billion RMB, up 8.53%, with operating profit and net profit attributable to shareholders both achieving double-digit growth, despite operating cost growth slightly exceeding revenue Core Income Statement Data (First Three Quarters of 2024) | Item | Jan-Sep 2024 (RMB) | Jan-Sep 2023 (RMB) | YoY Growth | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 1,060,429,057.46 | 977,117,684.48 | +8.53% | | Operating Cost | 585,377,707.53 | 533,573,798.76 | +9.51% | | Operating Profit | 200,748,192.53 | 179,727,480.99 | +11.70% | | Net Profit Attributable to Shareholders of the Parent Company | 166,726,371.77 | 143,918,861.68 | +15.85% | | Basic Earnings Per Share (RMB) | 0.57 | 0.49 | +16.33% | - Period expense analysis shows selling expenses remained largely flat; administrative expenses (+6.12%) and research and development expenses (+6.48%) maintained moderate growth, consistent with company scale expansion; financial expenses significantly increased due to higher interest expenditures13 Consolidated Cash Flow Statement Analysis In the first three quarters of 2024, net cash flow from operating activities reached 120 million RMB, up 8.73%, aligning with net profit growth and demonstrating robust cash generation, while investing activities continued to show net outflows for project construction Key Cash Flow Statement Data (First Three Quarters of 2024) | Item | Jan-Sep 2024 (RMB) | Jan-Sep 2023 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 119,902,354.35 | 110,278,463.08 | | Net Cash Flow from Investing Activities | -166,612,452.38 | -151,446,731.22 | | Net Cash Flow from Financing Activities | -216,218.46 | -66,567,170.30 | | Net Increase in Cash and Cash Equivalents | -46,569,109.30 | -105,633,899.67 | - Operating cash flow remained healthy, with cash received from sales of goods and rendering of services (1.127 billion RMB) exceeding total operating revenue (1.06 billion RMB) for the same period, indicating strong sales collection1215 - Net cash outflow from investing activities was 167 million RMB, primarily due to 214 million RMB paid for the acquisition of fixed assets, intangible assets, and other long-term assets16 - Cash flow from financing activities was largely balanced, including 389 million RMB from borrowings, 220 million RMB for debt repayment, and 172 million RMB paid for dividends, profits, or interest16

Well Lead-维力医疗(603309) - 2024 Q3 - 季度财报 - Reportify